

Meningococcal Disease (invasive)

Nine sporadic cases of invasive meningococcal disease (IMD) were reported in 2016, with no fatal outcomes reported. There were five cases of serogroup Y, and two cases each of serogroup B and W disease.

The median age of cases was 63 years and two-thirds of cases were over 40 years of age. The highest incidence rate was in males aged 15-19 years. The three cases under 20 years of age were all different serogroups (one each of serogroup B, W and Y).

None of the 2016 cases reported being immunized against the serogroup that caused their disease. Three of the serogroup Y cases reported underlying risk factors of malignancies/cancer treatment, however, these are not currently recommended indications for quadrivalent meningococcal vaccine. None of the other cases in 2016 reported underlying medical conditions.

The incidence of IMD has decreased from 0.7 cases per 100,000 population in 2007 to 0.2 cases per 100,000 population in 2016. This is partly due to a decline in serogroup C disease from 0.2 to 0 cases per


100,000 population from 2007 to 2016, reflecting the impact of the infant and school-age meningococcal C conjugate immunization programs.

With declining incidence of serogroup C disease, serogroup B had become the most commonly reported serogroup with incidence rates fluctuating between 0.09 to 0.4 cases per 100,000 population per year between 2007 and 2015. However, in 2016, there were only 2 cases of serogroup B disease (0.04 cases per 100,000 population).

The most common serogroup in 2016 was serogroup Y (0.1 cases per 100,000 population). Between 2007 and 2015, incidence rates of serogroup Y disease fluctuated between 0.04 and 0.2 cases per 100,000 population. A quadrivalent conjugate meningococcal vaccine was introduced for grade 9 students starting school year 2016/7 to provide protection against serogroup Y in late adolescence.




27.1 Meningococcal Disease (invasive) Rates by Year, 2007-2016




	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016
Reports	30	21	23	12	15	16	11	13	10	9
BC Rate	0.70	0.48	0.52	0.27	0.33	0.35	0.24	0.28	0.21	0.19
Canada Rate	0.69	0.59	0.62	0.45	0.50	0.43	0.34	0.28	0.29	-

27.2 Meningococcal Disease (invasive) Rates by HSDA, 2016



27.3 Meningococcal Disease (invasive) Rates by Age Group and Sex, 2016



27.4 Meningococcal Disease (invasive) Cases by Serotype and Year, 2007-2016

